echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Medical Research Articles > Insilico Announces Discovery of Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

    Insilico Announces Discovery of Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

    • Last Update: 2022-08-12
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    <>/* Style Definitions */ sp.


    Insilico Medicine Announces Novel 3CL Protease Inhibitor Preclinical Candidate for COVID-19 Treatment

    Insilico's preclinical drug candidate is an oral 3CL protease inhibit.


    .


    In the early days of the outbreak, in order to combat the new coronavirus, Insilicon used the data on the structure and characteristics of the coronavirus accumulated during the SARS outbreak in 2003 to train its end-to-end artificial intelligence drug research and development platfo.


    .


    The global epidemic caused by the new coronavirus has had a significant impact on human health and economic development, and brought serious challenges to global public health securi.


    Insilico is developing a rapidly growing portfolio of therapies at the forefro.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.